5 Key Takeaways

• 1

  A preclinical study presented at ACR Convergence 2024 explored p300 KAT inhibitors for modulating chronic inflammation.

• 2

  p300 KAT inhibitors target proinflammatory transcription factors like TNFα, IL-23, and IL-17A to downregulate key cytokines.

• 3

  The study found that p300 KAT inhibition suppresses transcriptional activation of proinflammatory genes without cytotoxic effects.

• 4

  Inhibition of p300 KAT led to decreased production of inflammatory mediators such as IL-6, IFNγ, and IL-22 in human immune cells.

• 5

  p300 KAT inhibitors significantly reduced joint swelling and inflammation in a rat model of collagen-induced arthritis.